Kirthi Varo, Derry Sheena, Moore R Andrew, McQuay Henry J
Pain Research and Nuffield Department of Anaesthetics, University of Oxford, West Wing (Level 6), John Radcliffe Hospital, Oxford, Oxfordshire, UK, OX3 9DU.
Cochrane Database Syst Rev. 2010 Apr 14(4):CD008041. doi: 10.1002/14651858.CD008041.pub2.
Migraine is a common, disabling condition and a burden for the individual, health services and society. Many sufferers choose not to, or are unable to, seek professional help and rely on over-the-counter analgesics. Co-therapy with an antiemetic should help to reduce nausea and vomiting commonly associated with migraine headaches.
To determine the efficacy and tolerability of aspirin, alone or in combination with an antiemetic, compared to placebo and other active interventions in the treatment of acute migraine headaches in adults.
We searched Cochrane CENTRAL, MEDLINE, EMBASE and the Oxford Pain Relief Database for studies through 10 March 2010.
We included randomised, double-blind, placebo- or active-controlled studies using aspirin to treat a discrete migraine headache episode, with at least 10 participants per treatment arm.
Two review authors independently assessed trial quality and extracted data. Numbers of participants achieving each outcome were used to calculate relative risk and numbers needed to treat (NNT) or harm (NNH) compared to placebo or other active treatment.
Thirteen studies (4222 participants) compared aspirin 900 mg or 1000 mg, alone or in combination with metoclopramide 10 mg, with placebo or other active comparators, mainly sumatriptan 50 mg or 100 mg. For all efficacy outcomes, all active treatments were superior to placebo, with NNTs of 8.1, 4.9 and 6.6 for 2-hour pain-free, 2-hour headache relief, and 24-hour headache relief with aspirin alone versus placebo, and 8.8, 3.3 and 6.2 with aspirin plus metoclopramide versus placebo. Sumatriptan 50 mg did not differ from aspirin alone for 2-hour pain-free and headache relief, while sumatriptan 100 mg was better than the combination of aspirin plus metoclopramide for 2-hour pain-free, but not headache relief; there were no data for 24-hour headache relief.Associated symptoms of nausea, vomiting, photophobia and phonophobia were reduced with aspirin compared with placebo, with additional metoclopramide significantly reducing nausea (P < 0.00006) and vomiting (P = 0.002) compared with aspirin alone.Fewer participants needed rescue medication with aspirin than with placebo. Adverse events were mostly mild and transient, occurring slightly more often with aspirin than placebo.
AUTHORS' CONCLUSIONS: Aspirin 1000 mg is an effective treatment for acute migraine headaches, similar to sumatriptan 50 mg or 100 mg. Addition of metoclopramide 10 mg improves relief of nausea and vomiting. Adverse events were mainly mild and transient, and were slightly more common with aspirin than placebo, but less common than with sumatriptan 100 mg.
偏头痛是一种常见的致残性疾病,给个人、医疗服务机构和社会都带来负担。许多患者选择不寻求或无法寻求专业帮助,而是依赖非处方镇痛药。联合使用止吐药应有助于减轻与偏头痛性头痛通常相关的恶心和呕吐。
确定阿司匹林单独使用或与止吐药联合使用,与安慰剂及其他活性干预措施相比,在治疗成人急性偏头痛性头痛方面的疗效和耐受性。
我们检索了考克兰中央对照试验注册库、医学期刊数据库、荷兰医学文摘数据库以及牛津止痛数据库,检索截至2010年3月10日的研究。
我们纳入了采用阿司匹林治疗离散性偏头痛发作的随机、双盲、安慰剂对照或活性药物对照研究,每个治疗组至少有10名参与者。
两名综述作者独立评估试验质量并提取数据。与安慰剂或其他活性治疗相比,实现各结局的参与者数量用于计算相对风险以及治疗所需人数(NNT)或伤害所需人数(NNH)。
13项研究(4222名参与者)比较了900毫克或1000毫克阿司匹林单独使用或与10毫克胃复安联合使用,与安慰剂或其他活性对照药(主要是50毫克或100毫克舒马曲坦)的效果。对于所有疗效结局,所有活性治疗均优于安慰剂,单独使用阿司匹林与安慰剂相比,2小时无痛、2小时头痛缓解及24小时头痛缓解的NNT分别为8.1、4.9和6.6,阿司匹林加胃复安与安慰剂相比,上述指标的NNT分别为8.8、3.3和6.2。50毫克舒马曲坦在2小时无痛和头痛缓解方面与单独使用阿司匹林无差异,而100毫克舒马曲坦在2小时无痛方面优于阿司匹林加胃复安的联合用药,但在头痛缓解方面并非如此;没有24小时头痛缓解的数据。与安慰剂相比,阿司匹林可减轻恶心、呕吐、畏光和畏声等相关症状,与单独使用阿司匹林相比,额外使用胃复安可显著减轻恶心(P<0.00006)和呕吐(P = 0.002)。与安慰剂相比,需要使用急救药物的阿司匹林使用者更少。不良事件大多轻微且短暂,阿司匹林组的发生频率略高于安慰剂组。
1000毫克阿司匹林是治疗急性偏头痛性头痛的有效药物,与50毫克或100毫克舒马曲坦效果相似。添加10毫克胃复安可改善恶心和呕吐的缓解情况。不良事件主要轻微且短暂,阿司匹林组比安慰剂组略常见,但比100毫克舒马曲坦组少见。